CD8A and neoplasm: Fig.4D shows that OT-II cells primed by A20-silenced BMMф are superior to those primed by control BMMф in inhibiting onset and growth of the engrafted OVA-expressed B6SJ003 tumor. However, treatment of A20-silenced BMMф/OT-II coculture with 100 nM of CMA for 1 hr prior to OT-II adoptive transfer ablates the superior ability of the OT-II cells in rejection of the engrafted tumor. Taken together, the results support that A20-silenced BMMфs not only elicit CD8+ T cells and NK cell to combat tumor, also effectively trigger cytotoxic CD4+ T cell response for anti-tumor immune protection.